We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two drug discovery approaches. The first approach is our TMAb™️ (Tumor Microenvironment Activated biologics) platform comprised of human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. Our lead program is targeting VISTA, a promising immune checkpoint inhibitor expressed on myeloid cells. Emerging nonclinical evidence has demonstrated that interaction of VISTA with its receptor (PSGL-1) is significantly enhanced by the acidic tumor microenvironment – a important differentiator of our research. We’re focused on unlocking the potential of VISTA with a human antibody and designed SNS-101 that selectively binds VISTA at low pH to activate T-cells and avoids on-target/off-tumor side effects, in preclinical studies.

The second approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

    -Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findingsRead More

  • Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data onRead More

  • Sensei Biotherapeutics to Present at BIO CEO & Investor Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )-- Sensei Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at theRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

    -Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findingsRead More

  • Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data onRead More

  • Sensei Biotherapeutics to Present at BIO CEO & Investor Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )-- Sensei Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at theRead More

Signup For Update

sign up for newsletter and get the latest update